

February 2, 2026

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
---	---

Dear Sir / Madam,

Sub: Clarification on Significant Volume Movement in Company's Shares

Ref : Your Letter No.: L/SURV/ONL/PV/APJ/ 2025-2026 / 890 dated February 1, 2026

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and with reference to your Email communication dated February 1, 2026 with subject – Volume Movement Letter, we wish to submit the following:

The Company has been making timely and adequate disclosures of all material events and information to the Exchanges, in strict compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We would like to inform you that the Government of India on January 29, 2026 has notified the imposition of a Minimum Import Price (MIP) on Penicillin-G, 6-Aminopenicillanic Acid (6-APA) and Amoxicillin Trihydrate, applicable to imports intended for domestic consumption. Lyfius Pharma Private Limited, a wholly owned subsidiary of the Company, is engaged in the manufacturing of Penicillin-G and downstream derivatives.

Thus, there has been some media coverage on the potential impact of MIP, details of which were already published as an official notification by the Government's DGFT website (<https://www.dgft.gov.in/CP/>), since all this information is already in public domain, there isn't anything concerning the Company specifically & exclusively which needs disclosure.

Thus, the recent increase in the trading volume of the Company's securities appears to be purely market driven. We confirm that there is no other information/announcement as on date (including any pending announcement) which, in the opinion of the Company, may have a bearing on the price/volume movement of its securities

We maintain continuous compliance with the disclosure obligations as per the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We request you to kindly take the above information on record.

Yours faithfully,

For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithriviham, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833

Email: info@aurobindo.com Website: www.aurobindo.com